Lipocine CEO Mahesh Patel buys $79,487 in company stock Nov 12-13.

Lipocine CEO Mahesh Patel made significant investments in his own company on November 12 and 13, 2026. On each of the two days, he purchased 25,000 shares of Lipocine Inc. (NASDAQ:LPCN) common stock, totaling $79,487. The shares were bought at prices ranging from $1.5796 to $1.5999 per share. After these transactions, Patel's beneficial ownership increased to 211,495 shares.

Despite the stock's price decline of 78.7% year-to-date, analysts suggest the company is undervalued. InvestingPro projections indicate Lipocine will be profitable in fiscal 2026, with an EPS forecast of $4.46. The company holds a strong balance sheet with more cash than debt. In other news, Lipocine began its Phase 3 BLOOM trial for LPCN1154, targeting severe postpartum depression, with first doses expected in Q4 2026.

The stock now trades at $1.71, with H.C. Wainwright maintaining a Neutral rating and a price target of $4.00. Additionally, Lipocine updated its sales agent fee agreement with A.G.P./Alliance Global Partners to a maximum of 3.0%.